Possible predictors for relapse from etanercept discontinuation in ankylosing spondylitis patients in remission: a three years' following-up study.

about

Possible predictors for relapse from etanercept discontinuation in ankylosing spondylitis patients in remission: a three years' following-up study.

Item

http://www.wikidata.org/entity/Q50508474

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Possible predictors for relaps ...... ree years' following-up study.

@en

Possible predictors for relaps ...... ree years' following-up study.

@nl

type

Item

label

Possible predictors for relaps ...... ree years' following-up study.

@en

Possible predictors for relaps ...... ree years' following-up study.

@nl

prefLabel

Possible predictors for relaps ...... ree years' following-up study.

@en

Possible predictors for relaps ...... ree years' following-up study.

@nl

P1476

Possible predictors for relaps ...... ree years' following-up study.

@en

P2093

Jieruo Gu

http://www.w3.org/2001/XMLSchema#string

Linkai Fang

http://www.w3.org/2001/XMLSchema#string

Minjing Zhao

http://www.w3.org/2001/XMLSchema#string

Pingping Zhang

http://www.w3.org/2001/XMLSchema#string

Zhiming Lin

http://www.w3.org/2001/XMLSchema#string

Zhongxing Luo

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis

Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia

Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial.

New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy.

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population.

Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment.

P304

87-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10067-017-3763-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28785857

http://www.w3.org/2001/XMLSchema#string